Nova Mentis Life Science Corp. (NOVA.CN)
CAD 0.01
(-50.0%)
CAD 0.01
(-50.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 841.66 Thousand CAD | 229.49% |
| 2022 | 255.44 Thousand CAD | -39.48% |
| 2021 | 422.05 Thousand CAD | 10.21% |
| 2020 | 382.96 Thousand CAD | 17.81% |
| 2019 | 325.07 Thousand CAD | 5.22% |
| 2018 | 308.95 Thousand CAD | 94.11% |
| 2017 | 159.16 Thousand CAD | 108.06% |
| 2016 | 76.5 Thousand CAD | -26.59% |
| 2015 | 104.21 Thousand CAD | -29.46% |
| 2014 | 147.74 Thousand CAD | -53.42% |
| 2013 | 317.15 Thousand CAD | -6.67% |
| 2012 | 339.82 Thousand CAD | 1274.12% |
| 2011 | 24.73 Thousand CAD | -69.15% |
| 2010 | 80.17 Thousand CAD | -7.12% |
| 2009 | 86.32 Thousand CAD | 26.67% |
| 2008 | 68.14 Thousand CAD | 242.84% |
| 2007 | 19.87 Thousand CAD | -65.23% |
| 2006 | 57.16 Thousand CAD | 1363.19% |
| 2005 | 3907.00 CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 995.07 Thousand CAD | 18.23% |
| 2024 Q2 | 1.07 Million CAD | 7.72% |
| 2023 Q3 | 654.93 Thousand CAD | 36.88% |
| 2023 Q1 | 343.45 Thousand CAD | 34.46% |
| 2023 Q2 | 478.45 Thousand CAD | 39.31% |
| 2023 FY | 841.66 Thousand CAD | 229.49% |
| 2023 Q4 | 841.66 Thousand CAD | 28.51% |
| 2022 FY | 255.44 Thousand CAD | -39.48% |
| 2022 Q2 | 164.18 Thousand CAD | -43.03% |
| 2022 Q4 | 255.44 Thousand CAD | 13.6% |
| 2022 Q1 | 288.18 Thousand CAD | -31.72% |
| 2022 Q3 | 224.86 Thousand CAD | 36.95% |
| 2021 FY | 422.05 Thousand CAD | 10.21% |
| 2021 Q4 | 422.05 Thousand CAD | -35.72% |
| 2021 Q3 | 656.55 Thousand CAD | 122.64% |
| 2021 Q2 | 294.88 Thousand CAD | 16.05% |
| 2021 Q1 | 254.09 Thousand CAD | -33.65% |
| 2020 Q1 | 271.04 Thousand CAD | -16.62% |
| 2020 FY | 382.96 Thousand CAD | 17.81% |
| 2020 Q2 | 262.03 Thousand CAD | -3.33% |
| 2020 Q3 | 290.1 Thousand CAD | 10.71% |
| 2020 Q4 | 382.96 Thousand CAD | 32.01% |
| 2019 Q4 | 325.07 Thousand CAD | -2.4% |
| 2019 Q1 | 281.91 Thousand CAD | -8.75% |
| 2019 FY | 325.07 Thousand CAD | 5.22% |
| 2019 Q2 | 360.86 Thousand CAD | 28.0% |
| 2019 Q3 | 333.06 Thousand CAD | -7.71% |
| 2018 Q4 | 308.95 Thousand CAD | 3.28% |
| 2018 FY | 308.95 Thousand CAD | 94.11% |
| 2018 Q1 | 181.11 Thousand CAD | 13.79% |
| 2018 Q2 | 162.13 Thousand CAD | -10.48% |
| 2018 Q3 | 299.14 Thousand CAD | 84.5% |
| 2017 Q1 | 109.4 Thousand CAD | 43.02% |
| 2017 Q4 | 159.16 Thousand CAD | 105.42% |
| 2017 Q3 | 77.48 Thousand CAD | -17.87% |
| 2017 Q2 | 94.34 Thousand CAD | -13.77% |
| 2017 FY | 159.16 Thousand CAD | 108.06% |
| 2016 Q3 | 201.96 Thousand CAD | 138.1% |
| 2016 Q2 | 84.82 Thousand CAD | -25.97% |
| 2016 FY | 76.5 Thousand CAD | -26.59% |
| 2016 Q1 | 114.59 Thousand CAD | 9.96% |
| 2016 Q4 | 76.5 Thousand CAD | -62.12% |
| 2015 Q1 | 108.45 Thousand CAD | -26.59% |
| 2015 Q3 | 167.24 Thousand CAD | 17.95% |
| 2015 Q4 | 104.21 Thousand CAD | -37.69% |
| 2015 FY | 104.21 Thousand CAD | -29.46% |
| 2015 Q2 | 141.79 Thousand CAD | 30.75% |
| 2014 Q4 | 147.74 Thousand CAD | 0.94% |
| 2014 Q1 | 263.25 Thousand CAD | -16.99% |
| 2014 FY | 147.74 Thousand CAD | -53.42% |
| 2014 Q3 | 146.36 Thousand CAD | -45.2% |
| 2014 Q2 | 267.11 Thousand CAD | 1.46% |
| 2013 Q2 | 257.67 Thousand CAD | 1.83% |
| 2013 FY | 317.15 Thousand CAD | -6.67% |
| 2013 Q4 | 317.15 Thousand CAD | -1.21% |
| 2013 Q3 | 321.05 Thousand CAD | 24.6% |
| 2013 Q1 | 253.03 Thousand CAD | -25.54% |
| 2012 Q4 | 339.82 Thousand CAD | 57.96% |
| 2012 Q3 | 215.13 Thousand CAD | 47.16% |
| 2012 Q1 | 61.6 Thousand CAD | 149.1% |
| 2012 FY | 339.82 Thousand CAD | 1274.12% |
| 2012 Q2 | 146.19 Thousand CAD | 137.32% |
| 2011 Q2 | 44.97 Thousand CAD | -49.46% |
| 2011 Q3 | 27.33 Thousand CAD | -39.23% |
| 2011 Q4 | 24.73 Thousand CAD | -9.53% |
| 2011 FY | 24.73 Thousand CAD | -69.15% |
| 2011 Q1 | 88.99 Thousand CAD | 11.0% |
| 2010 Q4 | 80.17 Thousand CAD | -63.42% |
| 2010 Q1 | 24.73 Thousand CAD | -71.35% |
| 2010 Q3 | 219.19 Thousand CAD | 85.11% |
| 2010 FY | 80.17 Thousand CAD | -7.12% |
| 2010 Q2 | 118.4 Thousand CAD | 378.77% |
| 2009 Q3 | 242.95 Thousand CAD | -19.45% |
| 2009 Q4 | 86.32 Thousand CAD | -64.47% |
| 2009 FY | 86.32 Thousand CAD | 26.67% |
| 2009 Q1 | 289.01 Thousand CAD | 324.09% |
| 2009 Q2 | 301.61 Thousand CAD | 4.36% |
| 2008 Q2 | 105.85 Thousand CAD | 553.99% |
| 2008 Q4 | 68.14 Thousand CAD | 111.31% |
| 2008 FY | 68.14 Thousand CAD | 242.84% |
| 2008 Q3 | 32.25 Thousand CAD | -69.53% |
| 2008 Q1 | 16.18 Thousand CAD | -18.57% |
| 2007 Q4 | 19.87 Thousand CAD | 34.74% |
| 2007 Q2 | 45.6 Thousand CAD | -3.8% |
| 2007 FY | 19.87 Thousand CAD | -65.23% |
| 2007 Q1 | 47.4 Thousand CAD | -17.08% |
| 2007 Q3 | 14.75 Thousand CAD | -67.65% |
| 2006 Q3 | 90.56 Thousand CAD | 563.89% |
| 2006 Q2 | 13.64 Thousand CAD | 0.0% |
| 2006 Q4 | 57.16 Thousand CAD | -36.88% |
| 2006 FY | 57.16 Thousand CAD | 1363.19% |
| 2005 FY | 3907.00 CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | 2.71 Million CAD | 69.054% |
| Asep Medical Holdings Inc | 3.05 Million CAD | 72.421% |
| BetterLife Pharma Inc. | 8.02 Million CAD | 89.506% |
| BioVaxys Technology Corp. | 3.48 Million CAD | 75.853% |
| ChitogenX Inc. | 6.71 Million CAD | 87.46% |
| Rapid Dose Therapeutics Corp. | 5.04 Million CAD | 83.311% |
| Defence Therapeutics Inc. | 4.06 Million CAD | 79.279% |
| Entheon Biomedical Corp. | 85.32 Thousand CAD | -886.407% |
| Gemina Laboratories Ltd. | 3.04 Million CAD | 72.327% |
| Glow Lifetech Corp. | 2.34 Million CAD | 64.126% |
| Lexston Life Sciences Corp. | 39.86 Thousand CAD | -2011.069% |
| Pharmala Biotech Holdings Inc. | 1.02 Million CAD | 18.208% |
| Doseology Sciences Inc. | 82.49 Thousand CAD | -920.295% |
| MYND Life Sciences Inc. | 5.77 Million CAD | 85.425% |
| PharmaTher Holdings Ltd. | 252.9 Thousand CAD | -232.803% |
| PreveCeutical Medical Inc. | 5.95 Million CAD | 85.877% |
| Telescope Innovations Corp. | 1.35 Million CAD | 37.702% |